Moderate (40 to 70%)
No clinically significant interactions have been identified. Screen drug specific interactions for interactions via CYP 1A2 and pharmacodynimc adverse effects.
Increased risk of nephrotoxicity when used concomitantly with other nephrotoxic agents.
EH Prescribing Restrictions
Tablets can be crushed for NG administration
No liquid formulation available
ValACYclovir is a prodrug of the antiviral acyclovir.
ValACYclovir is rapidly and nearly completely converted to acyclovir